Virotherapy Based on Oncolytic Adenovirus
A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Virology".
Deadline for manuscript submissions: 31 July 2026 | Viewed by 139
Special Issue Editors
Interests: microbial based immunotherapies; cancer immunology and imaging
Special Issues, Collections and Topics in MDPI journals
Interests: microbiology; host-pathogen interactions; microbial-based cancer therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Oncolytic virus-based therapy consists of genetically modified viruses that selectively infect, replicate within, and kill cancer cells while leaving normal cells unharmed and triggering an anti-tumor immune response. To date, multiple oncolytic viruses are being tested preclinically and clinically. One of them is T-VEC, a herpes simplex virus approved for injection directly into tumors in melanoma patients. Among all oncolytic viruses, oncolytic adenovirus (OAd) is the most widely tested vector due to its many advantages. This makes OAd an excellent virotherapy agent for targeting not only direct tumor lysis but also immunotherapy. Therefore, in this Special Issue, we invite you to submit research articles, review articles, and short communications that showcase current research in the area of “Virotherapy Based on Oncolytic Adenovirus,” including, but not limited to, virus engineering, combination therapy, immunotherapy, overcoming OAd limitations, etc.
Dr. Jorge G. Gomez-Gutierrez
Dr. Paul De Figueiredo
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- oncolytic
- adenovirus
- virotherapy
- immunotherapy
- combined therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
